08.04.24 | Vollzeit | Königsbrunn, Germering, Freisi | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Augsburg, Dachau, München, Lan | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Germering, Königsbrunn, Planeg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Dachau, Augsburg, Friedberg, L | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Dachau, Augsburg, Krailling, F | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Friedberg, München, Landsberg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen29.03.24 | Vollzeit | München | JobLeads GmbH | 100.000 € - 125.000 € And standard responses to frequently asked questions (FAQs); provide product-related site education; serve as medical resource for home office and field colleague training. Present medical and scientific information to healthcare professionals who provide peer education. Support Investigator Sponsored Trials
Später ansehen20.04.24 | Vollzeit, Teilzeit | Erlangen | www.karriere.uk-erlangen.deMedizinischer Fachangestellter Hochschulambulanz Kinderklinik (m/w/d) Pflegedienst 38.5 hours Fixed term of 24 months as of 01.07.2024 Eingruppierung gemäß TV-L Application deadline 27.04.2024 Universitätsklinikum Erlangen Pflegedienstleitung Kinderklinik Helga Bieberstein Loschgestraße 15 91054 Erl
Später ansehen20.04.24 | Vollzeit | Erlangen | www.karriere.uk-erlangen.deMedizinischer Fachangestellter Notaufnahme INZ (m/w/d) Pflegedienst 28.875 hours Fixed term of 24 months as of 16.06.2024 Eingruppierung gemäß TV-L Application deadline 28.04.2024 Universitätsklinikum Erlangen Pflegedienstleitung Internistisches Zentrum Peter Schäffler Ulmenweg 18 91054 Erlangen Con
Später ansehenVerpassen Sie nie wieder einen passenden Job!
Alle Jobs für Clinical Trial Assistant in Deutschland kostenlos abonnieren.